Study of KB803 eye drops for eye scrapes in DEB
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Injuries & trauma, Skin clinical trials.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of dystrophic epidermolysis bullosa (DEB) with a specific gene change.
- You must be at least 6 months old.
- You need to have a minimum number of painful eye surface scrapes (corneal abrasions) each month as defined by the study.
- You cannot be pregnant, nursing, or unwilling to use birth control during the trial.
- You cannot have started any new eye treatments or changed your eye care routine in the weeks before the study (except for artificial tears or preservative-free antibiotic drops).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This trial tests a new skin graft made with your own cells that have been genetically modified to produce a missing protein (collagen 7). It's for people with RDEB, a severe blistering condition, and aims to see if the graft can heal wounds safely.
This trial tests if a drug called Ev.FV can help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a condition that causes fragile, blistering skin. It is for people with open wounds on their arms, legs, or trunk that are a specific size.
Hear when a new Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.